Rubicon Organics Past Earnings Performance
Past criteria checks 0/6
Rubicon Organics has been growing earnings at an average annual rate of 30.4%, while the Pharmaceuticals industry saw earnings growing at 43.4% annually. Revenues have been growing at an average rate of 43.6% per year.
Key information
30.4%
Earnings growth rate
37.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 43.6% |
| Return on equity | -5.4% |
| Net Margin | -4.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Health Check: How Prudently Does Rubicon Organics (CVE:ROMJ) Use Debt?
Sep 25
Rubicon Organics Inc. (CVE:ROMJ) Soars 27% But It's A Story Of Risk Vs Reward
Jun 08Calculating The Fair Value Of Rubicon Organics Inc. (CVE:ROMJ)
May 06Is Rubicon Organics (CVE:ROMJ) A Risky Investment?
Mar 07Is Rubicon Organics (CVE:ROMJ) A Risky Investment?
Sep 28Benign Growth For Rubicon Organics Inc. (CVE:ROMJ) Underpins Stock's 26% Plummet
Jun 13Is Rubicon Organics (CVE:ROMJ) Using Too Much Debt?
Jun 06Would Rubicon Organics (CVE:ROMJ) Be Better Off With Less Debt?
Jan 09Here's Why Rubicon Organics (CVE:ROMJ) Can Afford Some Debt
Sep 19What Type Of Shareholders Own The Most Number of Rubicon Organics Inc. (CSE:ROMJ) Shares?
Jul 29
Revenue & Expenses Breakdown
How Rubicon Organics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 44 | -2 | 15 | 0 |
| 30 Jun 24 | 41 | -3 | 14 | 0 |
| 31 Mar 24 | 40 | -3 | 15 | 0 |
| 31 Dec 23 | 40 | -2 | 14 | 0 |
| 30 Sep 23 | 41 | -5 | 16 | 0 |
| 30 Jun 23 | 42 | -2 | 16 | 0 |
| 31 Mar 23 | 39 | -3 | 16 | 0 |
| 31 Dec 22 | 36 | -4 | 16 | 0 |
| 30 Sep 22 | 31 | -2 | 15 | 0 |
| 30 Jun 22 | 28 | -8 | 14 | 0 |
| 31 Mar 22 | 24 | -12 | 15 | 0 |
| 31 Dec 21 | 23 | -15 | 15 | 0 |
| 30 Sep 21 | 21 | -18 | 15 | 0 |
| 30 Jun 21 | 17 | -18 | 15 | 0 |
| 31 Mar 21 | 13 | -15 | 13 | 0 |
| 31 Dec 20 | 9 | -14 | 12 | 0 |
| 30 Sep 20 | 5 | -12 | 11 | 0 |
| 30 Jun 20 | 1 | -11 | 10 | 0 |
| 31 Mar 20 | 0 | -12 | 11 | 0 |
| 31 Dec 19 | 0 | -11 | 11 | 0 |
| 30 Sep 19 | -1 | -9 | 10 | 0 |
| 30 Jun 19 | -1 | -10 | 11 | 0 |
| 31 Mar 19 | 0 | -25 | 10 | 0 |
| 31 Dec 18 | 0 | -25 | 9 | 0 |
| 30 Sep 18 | 2 | -26 | 9 | 0 |
| 30 Jun 18 | 1 | -23 | 6 | 0 |
| 31 Mar 18 | 1 | -8 | 7 | 0 |
| 31 Dec 17 | 1 | -6 | 5 | 0 |
| 31 Dec 16 | 2 | 2 | 0 | 0 |
Quality Earnings: ROMJ is currently unprofitable.
Growing Profit Margin: ROMJ is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ROMJ is unprofitable, but has reduced losses over the past 5 years at a rate of 30.4% per year.
Accelerating Growth: Unable to compare ROMJ's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ROMJ is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-51.1%).
Return on Equity
High ROE: ROMJ has a negative Return on Equity (-5.43%), as it is currently unprofitable.